Gujarat Kidney to acquire 51 percent stake in UAE-based Blue Tree Clinics

Listed Co AcquisitionStrategic Transactions View source PDF Explain this filing

GKSL · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+0.7%Reaction day

₹131.22

prior close

₹133.61

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+1.4%-0.7% vs market

Hospital peers, median of 24sector+0.6%+0.1% vs sector

On the reaction day the stock moved 0.7 pts less than Nifty Microcap 250 and 0.1 pts more than its Hospital peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.9

10m

-1.3

15m

-1.2

30m

-1.2

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+0.7+1.4-0.7+0.6+0.1

Next day

+2.1+1.5+0.6+1.0+1.0

+0.6+0.5+0.1+0.6+0.0

+0.6+1.1-0.6+1.3-0.7

-1.7+0.7-2.4+0.5-2.2

-2.5-0.4-2.1+0.2-2.6

-1.5+0.5-2.0+0.1-1.6

15d

-3.2+0.1-3.3-0.1-3.1

+1.9+3.5-1.7+2.6-0.7

+32.5+5.8+26.7-1.2+33.7

+38.8+2.4+36.4-10.7+49.5

UpDownMarket · Nifty Microcap 250Sector · Hospital peers, median of 24Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Gujarat Kidney and Super Speciality Ltd will acquire 51 percent stake in Blue Tree Clinics LLC, a Dubai polyclinic offering plastic surgery, laser cosmetic, dental and chiropractic services. Deal value is about Rs 19.84 crore in cash, paid in two tranches within 50 days. Target FY25 revenue was 10.54 million AED and net profit 3.14 million AED. Not a related party transaction. Board also approved a postal ballot to change IPO object wording and appointed Dr Paresh Dhoti as independent director.

Likely market impact

Marks first international foray into UAE healthcare, broadening services beyond kidney specialty. Deal size is modest; execution and integration risks abroad remain.